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Abstract 
The therapeutic potential of cancer gene therapy has been limited by the difficulty of delivering 
genetic material to target sites. Various biological and molecular barriers exist which need to be 
overcome before effective non-viral delivery systems can be applied successfully in oncology. 
Herein, various barriers are described and strategies to circumvent such obstacles are discussed, 
considering both the extracellular and intracellular setting. Development of multifunctional delivery 
systems holds much promise for the progression of gene delivery, and a growing body of evidence 
supports this approach involving rational design of vectors, with a unique molecular architecture. In 
addition, the potential application of composite gene delivery platforms is highlighted which may 
provide an alternative delivery strategy to traditional systemic administration. 
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1. Introduction to Cancer Gene Therapy 
Cancer is a disease that arises as a result of unregulated DNA damage and mutation. Malignancies 
ensue when mutations in cell regulatory genes enable unopposed growth and division of cells. The 
aberrant nature of this growth leads to production of faulty and dysfunctional proteins which are 
associated with cancer progression. This genetic foundation of cancer marks it as an ideal target for 
genetic therapeutics. The polygenic nature of cancer results in substantial genetic heterogeneity 
which exists not only on a patient to patient basis, but between tumours from different locations 
within the same patient [1]. Consequently, approaches to cancer gene therapy can vary but the main 
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strategies can be categorised into suicide gene therapy, tumour suppressor therapy, antiangiogenic 
therapy or cancer immunotherapy [2].  
 
Several genes have been identified as major players in cancerous disease. The mutation of the 
tumour-suppressor gene p53 is implicated in many cancers and causes a loss of tumour suppressor 
function, thus promoting oncogenicity, and is associated with multidrug resistance and poorer 
prognosis [3]. Normally, p53 interacts with cellular pathways including the death-receptor pathways 
to suppress tumour growth [4], and the delivery of transgenes encoding p53 is a promising gene 
therapy strategy. The systemic administration of liposomal nanoparticles for delivery of the p53 
tumour suppressor gene, known as SGT-53, for advanced solid tumours was studied in a phase I 
clinical trial [5]. SGT-53 was administered to patients with a range of advanced cancer types 
including cervical cancer, thyroid cancer and colorectal cancer. Median survival was 340 days and 7 
of the 11 patients treated exhibited stable disease at 6 week assessment, with one patient 
reclassified from inoperable to operable due to significant tumour necrosis. This study is just one 
example of the potential which gene therapy holds in the treatment of cancer. As of 2016 there 
were over 2356 gene therapy clinical trials completed, in progress or approved worldwide, with 64% 
of these studies investigating cancer diseases [6]. 
 
However, currently only three products are licenced for gene therapy. Gendicine® and Oncorine® for 
the treatment of head and neck cancer are licenced in China and deliver p53 tumour suppressor 
genes. The only product licensed in the European Union is Glybera®, which can be used for the 
treatment of severe lipoprotein lipase deficiency [7]. The lack of licenced products is extremely 
disappointing considering the number of clinical trials on gene therapy, and highlights the difficulty 
in achieving regulatory approval. 
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2. Delivery of Genetic Material 
Gene therapy holds much promise for cancer treatment, however, a major disappointment and 
limiting factor in the progression of such novel therapeutics has been the lack of a comprehensive 
delivery vehicle. Various delivery systems are currently used in research, but to date no candidate 
has excelled to meet all the desired criteria for a successful gene delivery system, and generally each 
has major flaws and limitations. 
 
As yet, viral vectors are the most efficient gene delivery agents. Viruses have naturally evolved the 
ability to transfer genetic material into target cells. For this reason, viruses have been hijacked for 
gene delivery purposes [8]. Unfortunately, major safety concerns regarding mutagenesis, toxicity 
and immunogenicity in addition to limited capacity for nucleic acid carriage reduced the appeal of 
using viral vectors [9,10]. Consequently, and the proportion of clinical trials that employ retroviral 
vectors has declined from 28% in 2004 to 18.7% currently [11,12]. 
 
Non-viral gene delivery utilises a wide array of delivery systems including cationic polymers, 
liposomes, proteins and peptides which have the ability to package nucleic acids and deliver them 
into cells [13]. These approaches have shown promise for gene delivery, and have the potential to 
circumvent the problems associated with viral vectors [14]. However the transfection efficiencies of 
non-viral vectors are significantly lower than those of viral vectors [15]. Moreover, the complexity of 
design and assembly of non-viral vectors is not to be underestimated, as the numerous obstacles 
that face gene therapy must be considered. Several barriers exist, both extra- and intracellular, 
which destroy foreign genetic material, reduce transfection and prevent the introduction of 
therapeutic genes into cells. Successful gene therapy relies largely on the development of an 
efficient vector which can overcome these barriers to deliver the genetic material to its target site 
[16]. The ideal non-viral delivery vector must be non-toxic, non-immunogenic and multifunctional. 
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Table 1 highlights the properties of an ideal non-viral vector required to overcome various barriers 
to gene delivery.  
 
Table 1: Functional elements of a gene delivery vector required to evade various barriers to gene 
delivery 
Barriers to gene 
delivery  
Function required of delivery vector Rationale 
Extracellular 
Package and condense nucleic acids Particles are required to be a suitable size for in 
vivo delivery and cellular uptake, usually in the 
nano scale [17].  
Protect genetic cargo from 
degradation 
Protection from nucleases is vital to ensure the 
therapeutic is intact and functional when the 
target site is reached [18]. 
Avoid opsonisation and clearance 
from systemic circulation 
Opsonisation and rapid clearance by the RES 
system results in limited genetic material 
reaching the target site [19]. 
Target correct cells Specific and exclusive transfection of cancer cells 
will reduce off-target effects and may improve 
efficiency of the therapeutic [20]. 
Intra-cellular 
Stimulate internalisation to target 
cells 
Cellular uptake may be via a range of different 
endocytic pathways, facilitated by receptors or 
direct penetration [21,22]. 
Avoid/escape endosomal entrapment Escape from the endosome is vital to allow 
progression to the nucleus and avoid destruction 
of the therapeutic [23] 
Traffic DNA towards nucleus Movement through the cytosol towards the 
nucleus can be very slow and may be impeded 
by organelles [24].  
Promote nuclear import of DNA The nuclear envelope is the final barrier and 
active entry into the nucleus may be required for 
transcription and gene expression to occur [25]. 
 
Therefore, if gene therapy is to be truly successful, it is necessary to focus on the design of a delivery 
vehicle to fulfil the functional demands and satisfy the regulatory authorities. Herein, we will 
describe the most important barriers to nucleic acid delivery for gene therapy and discuss the 
various strategies that have been used or have potential to be used for delivery of genetic material 
for cancer gene therapy. 
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3. Extracellular Barriers 
 Mechanisms of clearance from systemic circulation 
Advanced cancerous disease are generally characterised by distant metastases that therefore dictate 
systemic delivery of treatment. This exposes the genetic therapy to a range of extracellular 
obstacles. The reticulo-endothelial system (RES), also known as the mononuclear phagocyte system 
(MPS) [26], poses a major threat to the journey and integrity of genetic material in the systemic 
circulation. Typically, clearance of gene delivery systems from the circulation occurs rapidly following 
systemic administration via opsonisation and phagocytosis [27]. Initial opsonisation marks 
undesirable material in circulation for phagocytosis, where macrophages engulf and either destroy 
or remove it from circulation [19]. Figure 1 demonstrates some of the extracellular barriers to gene 
delivery which exist following systemic delivery. 
 
 
Figure 1. Non-viral gene delivery vectors, delivered systemically, travel in the blood circulation to 
target malignant cells. Vectors must survive clearance from the reticuloendothelial system (RES) and 
extravasate from poorly structured blood vessels in the tumour, before endocytosis into tumour 
cells can occur.  
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Opsonisation is initiated by adsorption of plasma proteins in the blood stream to the surface of the 
foreign material. Up to 30 soluble plasma- and cell surface-bound proteins are known to be involved 
in this process, with complement components C3, C4, and C5 commonly involved [28]. A cascade of 
events is triggered where complement proteins covalently bind to the foreign material, tagging it for 
destruction by phagocytes which possess complement receptors (mainly CR1 or CD35) [29,30]. 
 
Phagocytosis and destruction of foreign material is then carried out by macrophages in the lungs and 
spleen, as well as Kupffer cells in the liver [27]. Kupffer cells are the resident macrophages in the 
liver which exist within the lumen of hepatic blood vessel walls, and play a central role in systemic 
defence [31]. Various destructive enzymes and chemical factors within macrophages degrade the 
unwanted material. In the case of non-biodegradable polymers however, this process has no 
significant effect, and fate of the polymer depends upon relative size and molecular weight. Particles 
larger than the renal threshold (usually >200 nm in size or >5000 Da MW) will be sequestered in an 
MPS organ (liver, lungs or spleen) [19]. Thus, biodegradability and a low molecular weight should be 
desirable criteria in the design of a delivery vector for systemic delivery of gene therapy, since the 
build-up of non-biodegradable materials in MPS organs could cause toxicity. 
3.1.1. Strategies to avoid clearance following systemic circulation 
Avoidance of the initial opsonisation process is critical if particles are to remain in circulation and 
circumvent clearance. The main parameters to consider for vector design here are particle size, 
surface charge and hydrophobicity. Particles above the renal threshold (>200 nm) and those with a 
cationic nature attract interaction with anionic blood proteins. Hydrophobicity also enhances the 
binding of complement proteins during the opsonisation process triggering sequestration by 
macrophages and clearance from circulation [18,32].  
 
Stealth molecules have been extensively used as a means of avoiding clearance and increasing 
circulation time of delivery systems administered parenterally. They are usually long hydrophilic 
7 
 
polymer chains which are flexible and have a neutral charge. They function to shield the delivery 
system from opsonins by reducing the electrostatic and hydrophobic interactions that trigger 
opsonisation, and also increase stability [19]. Increased stability of particles results in reduced 
aggregation as well as a decrease in off-target effects. The most widely studied stealth molecule is 
polyethylene glycol (PEG). PEG is extremely effective and has been added to various cationic delivery 
systems, increasing circulation times successfully. It also has regulatory approval due to its lack of 
toxicity or immunogenicity which makes it an extremely attractive component in the design of gene 
delivery systems [33]. Other polymeric compounds that have been used in the preparation of gene 
therapy nanoparticles include copolymers of lactic and glycolic acids, which have excellent 
biocompatibility, biodegradability and mechanical strength, and amphiphilic block copolymers, such 
as poly(lactide)–methoxy polyethylene glycol (PLA–mPEG), poly(lactide-co- glycolide) (PLGA)–mPEG, 
PLA–PEG–PLA and PLA–Tween 80, which have been shown to provide more effective performance 
for drug delivery both in vitro and in vivo than PEG alone [34]. Tactical engineering of PEGylated 
systems by adjusting surface coverage and use of different PEG molecular weights, chain densities 
and conformations can produce a vehicle with characteristics suitable for avoidance of opsonins 
[19].  Figure 2 exhibits the process of opsonisation and phagocytosis of a cationic delivery system 
and the use of PEGylation to avoid this. 
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Figure 2. (1) Opsonins (e.g. complement protein C3) rapidly bind to cationic gene delivery vectors 
and trigger phagocytosis by macrophages. As a result, the vectors are rapidly cleared from 
circulation and are unlikely to reach the target tumour. (2) Opsonisation and subsequent clearance is 
reduced with the addition of polyethylene glycol (PEG). The hydrophilic polymer forms a corona 
around the particles which reduces the binding of opsonin proteins and increases the circulation 
time of the vector, allowing it to reach the desired site. 
 Tumour microenvironment 
The tumour microenvironment is characterised by a chaotic, leaky vasculature and interstitial 
hypertension, which leads to acidic and hypoxic conditions. A range of extracellular proteases are 
produced which are known to degrade the extracellular matrix allowing for invasion and tumour 
progression. Together, these factors hinder drug distribution and reduce the therapeutic efficacy of 
nanoparticles as delivery to the target site is impeded [36].  
3.2.1. Exploiting the tumour microenvironment for drug delivery 
3.2.1.1. Leaky vasculature 
The ability of tumours to trigger angiogenesis for increased tumour blood supply is associated with 
more aggressive tumours, metastasis and poor prognosis. However, the rapid growth and mutation 
leads to a poorly structured and disordered vasculature that is functionally flawed. Normally, 
endothelial cells line the walls of blood vessels serving as a barrier between the blood circulation and 
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surrounding tissues. In the tumour microenvironment, however, endothelial cells are disorganised 
and irregularly shaped, causing abnormal vessel structure with loose interconnections resulting in 
leakiness [37]. This leakiness may be exploited for passive tumour targeting; a delivery system 
engineered to have a prolonged circulation time can extravasate from the blood stream 
preferentially at these leaky sites, resulting in retention and accumulation in the tumour site. 
Preferential release at tumour sites may be mediated by the enhanced permeability and retention 
(EPR) effect [33]. The EPR effect has been well documented and successfully exploited by various 
delivery systems. Many studies in animals have shown passive tumour accumulation of therapeutics, 
however this has not fully translated to studies in humans [35]. The literature can be contradictory 
on this topic with many opinions divided on the EPR effect. In addition, the heterogeneity which 
exists in tumour biology may affect the distribution and penetration of passive therapeutics, 
resulting in inconsistent, inadequate or restricted therapeutic effects [38]. Considering these 
shortcomings, total reliance on a passive targeting strategy of this nature may not be sufficient or 
reliable for cancer gene therapy. It is clear that a deeper knowledge of the tumour 
microenvironment is necessary to develop more active targeting strategies for efficient, reliable 
intra-tumoural delivery of gene therapeutics. 
 
Although PEGylation can improve the pharmacokinetic profile and biodistribution of therapeutics, it 
can limit cellular penetration once the target site is reached. This phenomenon, termed the PEG 
dilemma, can hinder gene expression by obstructing entry of delivery systems into tumour cells [39], 
probably due to the impact of PEG on particle size and particle-cell electrostatic interactions. To 
circumvent this, delivery systems that comprise detachable or cleavable PEG have been developed, 
whereby the PEG corona is shed once the vector has reached its target site. These ‘smart’ delivery 
systems can exploit conditions in the tumour environment such as pH and enzymatic activity to 
release the therapeutic. This also doubles as a targeting strategy, as release of the sheddable PEG 
should only be triggered in the tumour environment [40,41]. 
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3.2.1.2. Hypoxia and acidity 
An erratic and inadequate vasculature coupled with rapid growth results in areas within a tumour 
which are poorly perfused and hypoxic. Anaerobic glycolysis occurs in areas of hypoxia producing 
acidic metabolites such as lactic acid. This results in an acidic extracellular pH  that ranges from 5.7 
to 7.0, which is more acidic than blood (pH 7.4) [42,43]. The results of this defective respiration and 
metabolic disturbance are extremely important for tumourigenesis and are associated with 
treatment resistance and poor prognosis [44]. However, these conditions have also been exploited 
by smart delivery systems. 
 
Acid-sensitive linkages such as ester and hydrazine bonds have been used to conjugate PEG to 
delivery vectors. Once in the acidic tumour environment, the PEG chain is cleaved, exposing the 
cationic particle to cell membranes and initiating internalisation. Fella et al reported a 14-fold 
increase in transgene expression in HUH7 hepatocellular carcinoma tumours via a targeted polyplex 
system with PEG attached via an acid-labile hydrazone linkage when compared to the non-acid-
sensitive formulation following systemic administration [45]. pH sensitive block copolymers hold 
promise in the design of a vector which takes advantage of the tumour microenvironment. Li et al 
describe a pH-sensitive polymer, poly(L-histidine)–poly(lactide-co-glycolide)–tocopheryl 
polyethylene glycol succinate (PLH–PLGA–TPGS) for the delivery of Doxorubicin (DOX) for cancer 
chemotherapy. Functionalization with the pH-responsive polymer achieved 4.55-fold more 
cytotoxicity in MCF-7 breast cancer cells [34]. The pH responsive nature is due to the PLH 
component that has an unsaturated imidazole ring and becomes protonated in the acidic 
environment of the tumour causing the polymer to swell and release the drug within. Although this 
study does not describe the delivery of gene therapeutics, it is a good example of how a delivery 
system can be engineered for tumour targeting purposes and could potentially be modified for gene 
delivery applications. 
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3.2.1.3. Cancer-associated proteases 
Cancer-associated proteases (CAPs) are proteases that are often up-regulated in and characteristic 
of malignancies. Usually absent in healthy tissues, the CAPs include urokinase plasminogen activator 
(uPA), the matrix metalloproteases (MMPs), and cathepsins [46]. The presence of CAPs has been 
associated with aggressive disease and poor prognosis due to their involvement in invasion and the 
formation of metastatic lesions. Given their specificity for the tumour environment, vectors have 
been developed that are CAP-activatable.  
 
MMPs are a range of proteases which are commonly secreted by tumours and function in the 
degradation of the extracellular matrix, facilitating growth and progression of tumours [47]. In one 
study, the authors used an MMP-7-cleavable linker to tether PEG to polymeric nanoparticles for the 
delivery of anti-luciferase siRNA [48]. In vitro supplementation of MDA-MB-231 transfection medium 
with recombinant MMP-7 improved transfection efficiency 2.5-fold over that observed when MMP-7 
was absent. A nanoplatform which incorporates a peptide cross-linker including the MMP-2 
substrate sequence (GPLGVRGK) for MMP-responsive tumour delivery coupled with a tumour 
homing peptide (CRGDK) has been used to mediate cellular internalisation [49]. RGD peptide is a 
commonly used peptide targeting ligand and is involved in cell adhesion to cell surface integrins [50]. 
Integrin receptors such as αvβ3 integrin and related αv-integrins, are upregulated in various 
aggressive cancers and RGD has been incorporated into non-viral delivery systems for targeting 
tumours [51,52].  In vivo tumour-targeting efficacy of CRGDK-modified nanovesicles for delivery of 
Cy-5 labelled irinotecan was evaluated in HT-29 colon carcinoma tumour-bearing BALB/c nude mice 
and monitored by near-infrared (NIR) fluorescence imaging. Fluorescence was found to be 
significantly higher in the tumours of mice treated with the MMP-sensitive nanovesicles at 8 h to 24 
h post-injection compared to those treated with nanovesicles that lacked the MMP- sensitive linker. 
Furthermore, tumour growth delay of about 84.1% was observed when the nanovesicles were used 
to deliver irinotecan which was significantly more than other non-MMP sensitive treatment groups. 
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This study is a good example of how more than one targeting strategy can be used together to 
improve tumour delivery. The RGD peptide binds to integrin receptors on tumour cells and was 
useful for tumour homing, while the MMP-repsonsive peptide was cleaved by CAPs, allowing 
activation of the nanovesicles when present at the tumour site.  
 
4. Intracellular Barriers 
Many promising strategies have been employed which have the potential to navigate genetic 
material safely through the systemic circulation towards the target tumour. However, upon arrival at 
the tumour, a vector is met with a host of intracellular barriers, including the cell membrane, 
endosomal entrapment, immobility in the crowded cytoplasm and the nuclear envelope. Figure 3 
highlights the main intracellular hurdles which a vector must overcome before successful gene 
delivery can occur. 
 
Figure 3. (1) Once endocytosis occurs, the vector enters the endosomal compartment. If escape 
from the endosome is not facilitated, the vector will progress into a lysosome and be degraded. (2) 
Following endosomal escape, the therapeutic nucleic acid must be (3) trafficked towards and enter 
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the nucleus. (4) Transcription of the therapeutic DNA is followed by (5) translation and (6) 
expression of the therapeutic protein. 
 
It should be noted that some nucleic acid therapies have been developed, including small interfering 
RNA (siRNA) and microRNA, which require delivery to the cytosol of the cell, reducing the number of 
barriers to be overcome. However, for conventional gene therapy, therapeutic DNA requires delivery 
to the nucleus for transcription and thus, each intracellular barrier must be addressed in turn before 
successful gene delivery can occur.  
 Internalisation 
The cell membrane poses a major barrier to gene delivery since entry into cells is tightly controlled 
and regulated. The anionic lipophilic bilayer prohibits the entry of macromolecular anionic nucleic 
acids in their naked form [14]. Delivery systems for gene therapy work to condense therapeutic 
genetic material into a size suitable for cellular entry, usually ≤200 nm in diameter. Most DNA-
condensing systems are cationic in nature and mask the anionic charge of the nucleic acid, thereby 
enhancing the interaction with cell membranes through electrostatic interactions [17]. 
 
Factors that impact the cellular internalisation of a nano-scale entity include the size and charge of 
the entity, cargo properties, as well as cell type and cell surface receptors [53,54]. Endocytosis, 
which can be further categorised into clathrin-mediated [55], caveolae-mediated [56], or 
macropinocytosis [57]), is thought to be the main uptake pathway for most gene delivery vectors.  
 
The route of entry is important for gene delivery as it dictates the fate of the particle once 
internalised. This is particularly true for endocytic pathways, which usually culminate in endosomal 
entrapment with subsequent lysosomal destruction of the internalised vector. Some groups have 
proposed that another, more direct internalisation pathway (termed ‘transduction’) has served as a 
route of entry for cationic vectors, which does not involve endocytic or endosomal compartments. It 
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is suggested that transduction is triggered through non-specific electrostatic interactions between 
the cationic vector and anionic groups present on the cell membrane [58]. However, little is known 
about this entry mechanism, and further research is warranted, since avoidance of the endosomal 
compartment is an attractive option for non-viral gene delivery. By elucidating the precise entry 
mechanisms, it may be possible to improve cellular uptake efficiency with intelligent vector design 
and thus improve gene therapy outcomes. 
4.1.1. Improving cellular uptake 
Cationic non-viral delivery systems including polymers (e.g. poly-L-lysine (PLL), poly(ethylenimine) 
(PEI)) and lipids (e.g., 1,2-dioleoyloxy-3-(trimethylammonio)propane (DOTAP)) have been used to 
package DNA forming polyplexes and lipoplexes respectively [13]. However, problems with non-
biodegradability and toxicity [59] have led to increasing attention being paid to delivery systems 
which are biocompatible, have low toxicity and are easily fine-tuned [60,61]. DNA nanostructures 
have been developed as a non-cationic delivery platform compatible with biological systems. Recent 
advances in this field have resulted in development of 3D DNA nanostructures, e.g. DNA hydrogels 
and DNA tetrahedrons, which have the ability to deliver a range of cargo including drugs and nucleic 
acids into cells [62]. DNA tetrahedral nanostructures functionalised with folic acid for targeting of 
tumour cells expressing folate receptors were used to deliver anti-luciferase siRNA to BALB/c nude 
mice bearing luciferase expressing KB (HeLa) tumours [63]. Following systemic delivery via tail vein 
injection, luciferase expression was found to be significantly reduced by about 50%. However, this 
promising form of nanotechnology is a very recent advancement in the early stages of development, 
and much work is required to elucidate the exact functional mechanisms and physiochemical 
properties of these novel delivery systems. Peptide delivery systems have been extensively and 
successfully utilised for DNA delivery due to their dual function in DNA condensation and 
electrostatic interactions with anionic cell membranes facilitating internalisation.  
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Cell penetrating peptides (CPPs) have the ability to cross the cell membrane without the need for 
receptors or other carriers, via various mechanisms, including endocytic pathways or through direct 
translocation [64]. CPPs are now well established as successful delivery vectors, and are used 
extensively to enhance cellular uptake of a range of cargoes to various cell types [65]. TAT peptide 
(GRKKRRQRRR), which is derived from HIV-1 [66] has strong cell penetrating ability, consequent of 
its basic amino acids, lysine and arginine and was one of the first peptides to be used to facilitate 
cellular uptake of various cargo. Since then, novel CPPs have been derived which have a wide range 
of structures and characteristics, but generally CPPs can be cationic/basic, amphipathic or 
hydrophobic in nature [67]. 
 
Amphipathic CPPs are usually composed of an alpha helical structure with spatial separation 
between hydrophobic and hydrophilic amino acids residues. This structure is essential for their 
interaction and passage across the cell membrane with hydrophobic portions of the peptide able to 
insert into the lipid membrane, triggering uptake [68]. However, in the case of Penetratin peptide 
(RQIKIYFQNRRMKWKK), derived from the third helix of the homeodomain of Antennapedia [69], the 
peptide’s cationic nature was found to be responsible for cell penetration, rather than its helical 
structure [70]. Hence, the design of cationic CPPs with a more simple structure has gained attention, 
with the focus being on the inclusion of basic amino acid residues, namely arginine, lysine and 
histidine [71]. Particle internalisation is triggered by electrostatic interaction between the cationic 
CPPs and the anionic species (such as lipid head groups or proteoglycans) of the extracellular surface 
of the cell membrane [72]. Arginine residues have been shown to possess stronger cell-penetrating 
ability than lysine or histidine, owing to the guanidinium moiety in the arginine amino acid side 
chain, which is crucial for cell entry. As a result, arginine-rich peptides have been extensively 
researched, and oligoarginines have become well established CPPs [73–76]. 
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Octa-arginine (R8) is the most commonly used arginine-rich CPP, and is usually added to an existing 
delivery system to enhance the cellular uptake. R8 was coupled to a polymeric gene vector, 
composed of β-cyclodextrin (b-CyD) and low-molecular-weight poly-ethylenimine (PEI, MW 600) 
known as PC, to form nanovectors for highly efficient gene delivery to tumour cells. R8-involved 
complexes delivering luciferase plasmid DNA showed higher transfection efficiency in vitro in C6 rat 
glioma cells and A549 adenocarcinoma human alveolar basal epithelial cells than PEI 25 kDa 
complexes [77]. R8 has been shown to enhance the cellular uptake of various vectors and cargoes 
and as a result has become one of the most widely studied CPPs. 
 
Despite uncertainty surrounding the exact mechanism of internalisation, CPPs are very attractive 
agents for development of gene delivery systems [71]. CPPs do have shortcomings though, especially 
for in vivo applications, due to instability in systemic circulation and uncertain internalisation 
pathways. One method to improve the application of CPPs has been the use of unnatural or D-form 
amino acids which renders the peptide resistant to protease degradation, enhancing stability, 
however this does not address problems with opsonisation [78]. Despite this, CPPs have become 
well established as part of larger vector systems and often are incorporated to improve cellular 
uptake. 
 
 Endosomal entrapment 
The endosomal compartment has an integral cell regulatory function. It is responsible for monitoring 
material entering the cell. The endosome will either recycle matter to the cell membrane or direct it 
to lysosomes for degradation. Hence, the endosome represents one of the major limitations to 
efficient gene therapy. Generally CPPs, such as TAT and oligoarginines, lack the ability to escape the 
endosome resulting in poor transfection efficiencies [79,80]. In order to avoid destruction, a gene 
delivery system must facilitate escape from the endosome, which can be achieved through different 
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mechanisms, including increasing osmotic pressure so that the endosome bursts, or by causing 
leakage through pore formation in the endosomal membrane. 
4.2.1. Enhancing endosomal escape 
A number of strategies are employed by delivery systems to escape endosomal entrapment. The 
‘proton sponge effect’ is utilised by polymers and peptides rich in histidine. Histidine residues 
possess imidazole side chains which become protonated in the acidic conditions causing an influx of 
water and buffering of the endosome resulting in swelling and bursting, releasing the endosomal 
contents [81,82]. H5WYG is a histidine-rich peptide, derived from the HA2 subunit of haemaglutinin 
(HA) protein of the influenza virus, which has improved gene delivery by facilitating endosomal 
escape [83]. A two-fold increase in luciferase mRNA level was detected by Asseline et al when 
H5WYG was added to an antisense oligonucleotide (2’-Ome RNA705) targeting aberrant splicing of 
luciferase pre-mRNA in HeLa pLuc705 cells [84]. The importance of the histidine residues was 
highlighted in a study conducted by Lo et al where the addition of 10 histidine residues to TAT 
increased luciferase transgene expression up to 7000-fold in the human glioma cell line U251 in vitro 
[85]. 
 
Membrane destabilisation is a mechanism of endosomal escape that is employed by fusogenic 
peptides, which occurs through interaction between the cationic amino acids and the anionic lipids 
in the endosomal membrane, forming pores which disrupt the membrane and cause leakage [86]. 
Once inside the endosome, the acidic pH triggers a conformational change in the helical structure of 
fusogenic peptides which leads to interaction and disruption of the phospholipid membrane of the 
endosome [23,67]. Liou et al described the functionalisation of nona-arginine (R9) with the fusogenic 
hemagglutinin-2 (HA2). Following tagging of the vector with red fluorescent peptide (RFP), A549 
human lung carcinoma cells were found to have significantly more RFP levels in vitro when treated 
with the R9-HA2 peptide than those treated with R9 alone [87]. 
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RALA (WEARLARALARALARHLARALARALRACEA) is a fusogenic amphipathic peptide with a cationic 
nature which has multifunctional activity for gene delivery [88]. RALA was rationally derived from 
the first cell-penetrating amphipathic peptide demonstrated to possess fusogenic activity named 
GALA (WEAALAEALAEALAEHLAEALAEALEALAA), and its derivative KALA 
(WEAKLAKALAKALAKHLAKALAKALKACEA) [23]. The arginine residues give RALA its cationic nature, 
enabling DNA condensation and interaction with cell membranes. Further to this, the alpha helical 
amphipathic structure undergoes a conformational change in the acidic endosome facilitating 
endosomal escape resulting in DNA transfection rates which are comparable to that of the 
commercially available transfection agent Lipofectamine 2000 [76,88].  
 
RALA has potential for a wide range of applications and has the capacity to deliver various types of 
nucleic acid therapeutics (and other anionic cargo) [89]. RALA was used to deliver the FK506-binding 
protein like – FKBPL gene (pFKBPL) – a novel member of the immunophilin protein family [90]. 
Overexpression of FKBPL has been shown to inhibit angiogenesis, tumour growth and stemness, 
through a variety of mechanisms. RALA delivered both overexpressing pFKBPL and  downregulating 
siFKBPL in a non-toxic manner. In vivo, RALA/pFKBPL delivery retarded tumour growth, and 
prolonged survival with an associated decrease in angiogenesis, while RALA/siFKBPL had no effect on 
tumour growth rate or survival, but resulted in an increase in angiogenesis and stemness. This study 
demonstrates the adaptability of RALA for the delivery of both plasmid DNA and other nucleic acid 
therapeutics for effective gene delivery.  
 Nuclear Trafficking 
Following successful endosomal escape, a gene delivery vector is released into the cytoplasm. In the 
case of RNAi therapeutics, this is sufficient. However, DNA requires delivery to the nucleus for 
transcription. Movement of macromolecules through the cytoplasm is greatly restricted due to 
overcrowding of organelles, the cytoskeleton of the cell and high protein concentrations which slows 
mobility of the vector and exposes it to the degradative action of endonucleases [91,92]. For 
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successful transfection to occur, the gene delivery vector must protect the cargo and actively traffic 
the nucleic acid payload towards the nucleus. 
4.3.1. Trafficking towards the nucleus 
The cell cytoskeleton maintains the organelles of the cell in a functional location through the action 
of microtubules and motor proteins [93]. Microtubules have motor proteins, namely dyneins and 
kinesins, which move along the tubules in different directions and are responsible for intracellular 
transport of vesicles, lysosomes and endosomes [94]. It has been observed that plasmid DNA utilises 
microtubules, in particular dyneins, for transport towards the nucleus [95]. A number of viruses are 
known to exploit this host machinery to facilitate access to the nucleus [96], although little is known 
about the exact mechanisms and binding domains used by viruses [97]. For example, the motif 
sequence contained in the viral capsid hexon of the adenovirus (E3-14.7K peptide: 
VVMVGEKPITITQHSVETEG) promoted microtubule-mediated transport of plasmid DNA [98]. 
Conjugation of a plasmid encoding luciferase with E3-14.7K resulted in increased transfection 
efficiency up to 60% in HeLa cells, compared to 30% when conjugated to a control peptide. 
Incorporation of this sequence into the design of a non-viral vector may therefore improve 
transfection efficacy. 
 
Acetylation of microtubules gives enhanced interactions with and trafficking of plasmid DNA. It has 
been observed that increasing the levels of acetylated tubulin through inhibition of the tubulin 
deacetylase HDAC6, results in more rapid plasmid nuclear localisation and greater levels of gene 
transfer. Therefore if a vector was capable of acetylating microtubules or inhibiting their 
deacetylation, then transfection efficiency may be improved [99]. Transcription factors, such as 
cyclic AMP response-element binding protein (CREB), are also implicated in the complex transport 
network and have been shown to be involved in facilitating movement of plasmid DNA towards and 
into the nucleus [100]; these transcription factor binding sites could be incorporated into plasmids to 
facilitate shuttling to the nucleus.  Various transcription factors are implicated as having roles in 
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transport of plasmids to the nucleus, and further study to elucidate the exact mechanisms could lead 
to more efficient DNA delivery vehicles for nuclear entry. The possibility of multiple transcription 
factors involved in speeding up nuclear delivery could also be important for avoiding degradation by 
nucleases in the cytoplasm [101].  
 
Dynein is a multi-unit protein complex with various components capable of binding cargo. These 
subunits, especially the light chains such as Rp3, TcTex1 and LC8 are exploited by many viruses 
during infection and have been incorporated into some vectors with success [102]. A modular 
protein that combined TAT peptide and the dynein light chain Rp3 (T-Rp3) provoked transgene 
expression 7.5-fold more potently in HeLa cells than TAT alone, demonstrating the importance of 
microtubule transport [103]. In addition, T-Rp3 achieved transfection efficiency comparable to that 
of Lipofectamine, while being considerably less toxic to cells. Similarly, a recombinant fusion protein 
based on the dynein light chain LC8 facilitated plasmid DNA uptake into HeLa cells and transported 
DNA via microtubules to the nucleus for GFP transgene expression [102]. However, it is important to 
characterise the specificity of these binding units, since exogenous proteins may compete with 
vectors for binding, which could be detrimental to transfection efficiency [98].  
 
 Nuclear envelope  
The nuclear envelope is a bilayer which protects the contents of, and tightly controls entry into the 
nucleus through the action of the nuclear pore complex (NPC) [104]. Passive entry into the nucleus is 
restricted to molecules less than 10 nm in diameter, which excludes the entry of DNA, and is the 
final barrier that needs to be overcome for successful DNA delivery.  
4.4.1. Facilitating nuclear import 
The nuclear pore tightly controls nuclear entry, but during cell division it is temporarily 
disassembled, and delivery of pDNA to nucleus during this period has been investigated. Symens et 
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al found that coupling chromatin-targeting peptides to polystyrene beads or pDNA complexes 
improved inclusion in the nucleus by 2- to 3-fold when using Xenopus Nuclear Envelope Reassembly 
(XNER) Assay [105]. However, following microinjection in living HeLa cells, no nanoparticles were 
observed in the nuclei of cells post-division but accumulated in the perinuclear lysosomal 
compartment. Further to this, Remaut et al evaluated pDNA delivery in dividing cells using 1) 
phosphorylation responsive peptides that release pDNA preferentially during mitosis and 2) 
chromatin targeting peptides to anchor pDNA in newly formed nuclei upon cell division [106]. Each 
peptide was used to deliver pDNA encoding GFP in combination with a lipid-based carrier to HeLa 
cells. The phosphorylation peptide resulted in a slight increase in transfection efficiency of about 
30%; however the chromatin targeting sequence was not responsible for any improvement in 
transfection efficiency. Based on these studies, it seems that nuclear entry of foreign plasmid DNA is 
tightly controlled regardless of cell division stage and reliance on nuclear disassembly may not be as 
successful as first thought. 
 
Nuclear localisation signals (NLS) are short sequences of basic amino acids that facilitate entry of 
cargo through the nuclear envelope, and have proved an valuable addition to vector design for gene 
delivery [25,107]. Nuclear entry facilitated by the NLSs from simian virus 40 (SV40), large tumour 
antigen (PKKKRKV) and Rev peptide (RRNRRRRWRERQRQ) rely particularly on arginine content 
[108,109]. A number of NLSs contain arginine-rich portions, such as TAT, Rev and Rex proteins of the 
retroviruses, and the tegument proteins (VP13/14) of the herpes simplex virus (HSV) type 1, which 
are responsible for nuclear import via the importin β pathway [110–112]. This holds significance for 
vector design since the inclusion of arginines may elicit the assistance importin β for trafficking 
towards the nucleus as well as entry to the nucleus [113]. However, there are some limitations to 
the use of NLSs, since DNA binding can be weak and covalent conjugation may hinder functionality 
[107,114]. As a result, NLSs should not be used in isolation but rather as supplements to existing 
vectors. For example functionalization of R8 with the SV40 NLS provoked transfection efficiency that 
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was almost as effective (80%) as jetPEITM(transfection reagent), but lacked jetPEITM’s cytotoxicity in 
HeLa cells [115].  
 
5. Targeting 
To increase specificity for diseased tissue, and to limit off-target toxicity, targeting strategies are 
often employed in gene delivery vehicles. Cancer cells have unique distinguishing characteristics 
from normal healthy cells, which often manifests in aberrant protein and receptor expression [116]. 
Commonly overexpressed proteins include integrins [117], transferrin receptors [118], epidermal 
growth factor receptors (EGFR) [119], folate receptors [120] and proteoglycans [121]. This 
represents a major target for tumour-selective gene delivery, and vectors engineered with ligands 
can increase specificity and efficacy of therapeutics, thereby reducing side effects [122]. 
Furthermore, cellular uptake of gene delivery vectors may be enhanced via receptor-mediated 
endocytosis, and as a result much research has focused on active targeting strategies. 
 
The advancement of phage display libraries and molecular modelling have accelerated the discovery 
of potential targeting peptides which are specific to cancer cells. A cell-penetrating-homing peptide 
(CPHP), termed RLW (RLWMRWYSPRTRAYG) was found to selectively target and penetrate A549 
non-small cell lung cancer cells via an unknown mechanism [123]. RLW-functionalised PEG-PCL 
nanoparticles loaded with infrared dye preferentially targeted A549 over U87 xenografts. 
Functionalization with RLW also improved vector pharmacokinetic profile, with vector accumulation 
being barely detectable in organs, relative to vectors functionalised with R8 [124]. Although this 
strategy holds promise, the potential application is limited to use in one specific cancer and so there 
is a need to discover more peptides suitable for targeting various diseases. 
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Yang et al used phage peptide display to identify a 5-amino acid peptide termed TMTP1 (NVVRQ), 
which binds to metastases [125]. They demonstrated that TMTP1 specifically bound to a series of 
highly metastatic tumour cells, including prostate cancer PC-3M-1E8, breast cancer MDA-MB-435S, 
lung cancer PG-BE1, and gastric cancer MKN-45sci, in vitro and in vivo, but not to poorly metastatic 
or non-metastatic cell lines. Fluorescently labelled TMTP1 administered systemically to tumour-
bearing mice strongly and specifically targeted micro-metastases.  
 
TMTP1 was incorporated successfully into biopolymers and used to deliver pEGFP-N1 reporter 
plasmid DNA to a range of prostate cancer cells. Two of the biopolymers (RMHT and RM3GT) 
effectively condensed the plasmid DNA into cationic nanoparticles <100 nm and were capable of 
transfecting PC-3 metastatic prostate cancer cells. With both RMHT and RM3GT, a higher 
transfection efficacy was observed in PC-3 cells than in the moderately metastatic, DU145, and 
normal, PNT2-C2, cell lines. Furthermore, blocking of the TMTP-1 receptors inhibited gene transfer 
indicating internalization via this receptor [126]. The ability to specifically target highly aggressive 
disseminated metastatic lesions is highly attractive for gene delivery and therefore TMTP1 has many 
potential applications. 
 
6. Multifunctional Delivery Systems 
The complex nature of systemic delivery of gene therapy requires the vector to overcome numerous 
barriers and challenges and ultimately requires a multifunctional system. Engineering strategies 
involving PEGylation and targeting ligands have potential to overcome some specific barriers but a 
multifunctional system must have the capacity to overcome all the barriers to gene delivery. 
Extensive research has focused on the design and production of such a vector with some promising 
prototypes being produced [127]. 
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 Multifunctional envelope-type nano devices (MENDs) 
Multifunctional envelope-type nano devices (MEND) have been produced by Harashima et al 
through clever design and a ‘programmed packaging’ concept. These nanovectors comprise a core 
DNA-condensing cationic polymer, PLL, wrapped in a lipid envelope functionalised with various 
components including targeting ligands, PEG, CPPs and endosomolytic peptides [128]. Originally the 
MEND systems were relatively straightforward, but have evolved to a more intricate and robust 
delivery systems. A MEND composed of a PLL DNA-condensing core, enveloped in a lipid 
functionalised with stearylated R8 provoked anti-luciferase siRNA transfection that was equipotent 
to Lipofectamine 2000 without any detectable cytotoxicity [129]. Since then, MENDs have evolved 
from this non-selective system to active targeting vectors [130].  
 
Modification of the MEND system is relatively easy and has allowed for numerous changes and 
functionalistions.  Functionalization of R8-MEND (capable of potent transfection in HeLa cells [131]) 
with INF7, a pH-sensitive endosomal escape motif (derived from the HA2 protein of the influenza 
virus envelope) produced R8/INF7/MEND, which evoked 240- and 115-fold higher luciferase 
expression in mouse liver and spleen than R8-MEND, respectively [132]. This showed the potential 
for this delivery system to evoke strong in vivo gene expression, although expression in the liver and 
spleen is indicative of off-target gene expression and possible sequestration by the MPS system.  
 
In an attempt to avoid the MPS system, a MEND was functionalised with PEG attached via a MMP-
cleavable linker. As described previously, PEGylation may inhibit both uptake and endosomal escape 
of vectors, so a cleavable linker was included to create a sheddable PEG which is cleaved in an MMP-
rich tumour environment. The MEND was also functionalised with R8 for cellular entry and the pH-
sensitive fusogenic peptide GALA for endosomal escape [133]. The PEGylated GALA/R8/MEND, used 
to deliver anti-luciferase siRNA, efficiently silenced luciferase expression in HT1090-luc xenografts, 
while an unmodified MEND showed a small silencing effect and the PEG-MEND showed no effect.  
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This study highlights the importance of a step-wise, intelligent design process in the production of 
gene delivery systems. The MEND system has produced very promising results and with further 
modifications and fine-tuning, these systems have potential as successful gene delivery agents. 
 Designer Biomimetic Vectors 
Despite the potential of the MEND system, their production can be quite complex with multiple 
conjugation steps. An exciting emerging approach is the use of recombinant DNA technology to 
produce bio-inspired fusion proteins, termed designer biomimetic vectors (DBVs) or designer 
biopolymers (DBPs), which comprise several peptide motifs, each with distinct functionality [134]. 
Generally, DBVs possess a DNA-condensing motif (DCM), endosomal disruption motif (EDM), nuclear 
localisation motif (NLS) and targeting motif (TP) [15,135].  
 
KALA-2H1-NLS-TP is a DBV that comprises two repeating units of histone H1 (2H1) for DNA 
condensation, KALA for pH-dependent endosome escape, a cyclic targeting peptide (TP) which 
targets antigens on the surface of ZR-75-1 breast cancer cells, and Rev for nuclear localisation [81]. 
KALA-2H1-NLS-TP preferentially targeted ZR-75-1 cells, resulting in gene transfection efficiency that 
was more impressive than that produced by DBV derivatives that lacked one or more functional 
motifs. McCarthy et al used a similar DBV for the delivery of iNOS gene therapy targeted to breast 
cancer and found promising therapeutic effects in vitro [136]. Another recombinant protein, tetra-
H2A (TH), that comprises four tandem repeats of human histone H2A peptide, interspersed with 
cathepsin D cleavage sites and GALA to facilitate the endosome escape of the cargo, was used to 
condense siRNA, before being coated in a cationic lipid and functionalised with PEG to give Lipid-
tetra-H2A-Hyaluronic acid (LHH) nanoparticles [137]. This approach has been adopted in an attempt 
to mimic lipid-enveloped viruses which naturally have impressive transfection abilities. Following 
systemic delivery of LHH nanoparticles loaded with anti-luciferase siRNA to H460-luc xenograft-
bearing mice, a ~66% silencing of luciferase expression was observed, highlighting the potential of 
such vectors for in vivo applications. 
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Through insightful design and optimisation, DBVs represent progress towards the production of 
artificial viruses for gene delivery. Recombinant DNA technology allows control of vector 
characteristics at the molecular level which are easily modifiable for enhancement and optimisation 
of functionality [138]. This promising area of research however, requires much more investigation 
and optimisation. To-date, only proof-of-concept evidence exists - further in vivo work with 
therapeutic transgenes is ultimately required to validate the concept. Table 2 summarises some of 
the key components and activity of MENDs and DBVs, allowing comparison of the multifunctional 
systems. 
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Table 2: Summary of state-of-the-art MEND and DBV delivery systems. 
Name 
Functionality 
Genetic 
material 
delivered Activity 
DNA 
condensation Cell entry 
Endosomal 
escape 
Nuclear 
entry 
Other 
e.g. targeting 
moiety, 
PEGylation 
R8/IN
F-7 
MEN
D 
Protamine R8 
peptide 
INF-7 peptide 
derived from 
N-terminal 
domain of 
the HA2 
protein 
influenza 
virus 
envelope 
Protamine - Plasmid 
DNA 
encoding 
luciferase 
reporter 
gene 
Luciferase 
transgene 
expression levels 
240-fold higher in 
liver and 115-fold 
higher in spleen 
than that of the 
R8-MEND in vivo 
[132]. 
GALA
/PPD 
MEN
D 
Stearylated 
octahistidine 
(STR-H8)   
GALA 
peptide 
derived 
from HA2 
pH-
responsive 
fusogenic 
GALA peptide 
N/A  
(siRNA 
delivery to 
cytosol) 
MMP-
cleavable PEG 
 
anti-
luciferase 
siRNA 
Intratumoural 
injection of 
PPD/GALA- MEND 
HT1080-luc into 
human 
fibrosarcoma 
mouse xenografts 
resulted in more 
efficient luciferase 
gene silencing 
compared with 
unmodified 
MENDs in vivo 
[133]. 
KALA-
2H1-
NLS-
TP 
DBV 
Two 
repeating 
units of 
histone H1 
(2H1) 
KALA 
peptide 
KALA peptide 
(fusogenic) 
NLS from 
Rev 
protein of 
HIV virus 
ZR-75-1 
targeting 
peptide 
(RVCFLWQDGR
CVF) 
Plasmid 
DNA 
encoding 
luciferase 
reporter 
gene 
Transfection 
efficiency of 
luciferase 
comparable to PEI 
25 kDa with 
preferential 
targeting to ZR-75-
1 breast cancer 
cells [81]. 
DBV µ peptide 
derived from 
adenovirus 
Receptor 
mediated 
(HER2 
affibody) 
H5WYG 
histidine-rich 
peptide, 
derived from 
the HA2 
Rev 
peptide 
(RRNRRRR
WRERQRQ
) derived 
from 
retrovirus 
HER2 affibody 
targeting 
moiety 
attached via 
cathepsin 
substrate (CS) 
for cleavage in 
the endosome 
Plasmid 
DNA 
encoding 
iNOS gene 
DBV-mediated 
iNOS gene delivery 
resulted in a 
maximum of 62% 
cell killing and less 
than 20% 
clonogenicity in 
ZR-75-1 breast 
cancer cells in 
vitro [136]. 
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 Composite delivery systems 
Some research ventures have sought an alternative to repeated parenteral delivery which is not 
ideal from a patient comfort and compliance standpoint. The nanoparticulate delivery systems 
discussed so far show great potential for overcoming barriers to gene delivery with impressive 
transfection efficiencies, but this may be further optimised if combined with another delivery 
platform to produce composite materials. Alternative delivery strategies which hold promise for 
gene delivery include hydrogel matrices for prolonged release depot injections and microneedles for 
the delivery of DNA vaccines. 
6.3.1. Hydrogel scaffolds 
Hydrogels are biocompatible scaffolds that are commonly used for localized therapy such as tissue 
engineering. They have desirable characteristics including a hydrated state and tissue-like 
environment and provide a scaffold structure that can be easily tailored. Hydrophilic polymers, 
which may be of natural or synthetic origin, form hydrogels through crosslinking or self-assembly. 
Controlled release of encapsulated materials can be achieved through optimising pore size, vector-
scaffold interactions and/or degradation rate, thus making hydrogels good candidates for gene 
delivery depot formulations [139]. A composite system based on biodegradable folate-poly(ester 
amine) polymer and thermosensitive hydrogel PECE (PEG-PCL-PEG) for sustained gene release 
achieved transfection efficiency of 40% in C26 colon carcinoma cells, with negligible toxicity [140]. 
Further to this, prolonged release of DNA was observed in vitro over a seven day period from the FA-
PEA/DNA encapsulated PECE hydrogel, with DNA release of 18% (3.6 µg) by the end of day 3, 
followed by a period of slow release of 0.5 µg per day. This highlights the potential of a composite 
hydrogel system as a prolonged release system and this approach could be especially useful for local 
delivery which would avoid any potential for systemic off-target effects. However, this area of 
research is very much in its infancy and further in vitro and in vivo work is required. Investigation of 
29 
 
release profiles, toxicity, biodegradability, compatibility of vectors with hydrogel formulations and in 
vivo efficacy will be needed before these systems can progress further.  
6.3.2. Microneedles  
An effective alternative to parental drug delivery has been the production of transdermal delivery 
systems, particularly non-invasive microneedles. Microneedles have gained much attention in the 
pharmaceutical field since they present a novel way of overcoming the stratum corneum, a major 
barrier to transdermal drug delivery of a wide range of drugs and vaccines [141]. A range of 
microneedle formulations exist, including hollow, solid, coated, dissolvable and hydrogel forming 
microneedles, and microneedles are produced using a variety of materials [142].  
 
DNA vaccination for cancer immunotherapy is one application where microneedles may improve 
treatment outcomes. DNA vaccines require cellular delivery of plasmid DNA to induce expression of 
the encoded antigen, which provokes the cytotoxic immune system to clear the antigen-presenting 
cells [143,144]. Delivery of DNA vaccines to the skin has great potential, since it is a highly 
immunoreactive environment containing abundant immunologically active dendritic cells that 
process foreign antigens and prime effective immune responses [145]. A CPP-PEI copolymer grafted 
with mannose (CPP-PEI1800-Man) was used to package a DNA vaccine for malignant melanoma. The 
DNA vaccine, comprised of a plasmid Trp2-GM-CSF-Fc-EGFP, was delivered in solution following 
application and removal of a solid microneedle array, and evoked adaptive T cell immune responses, 
important for effective immunotherapy [146]. Significantly higher levels of cytokines, including IFN-γ 
and IL-12 were observed in B16 melanoma xenograft-bearing BALB/c mice that were vaccinated with 
CPP-PEI1800-Man/pTrp2-GM-CSF-Fc-EGFP than those observed in mice treated with naked DNA. 
Large numbers of CD4+ and CD8+ T cells were found to infiltrate the solid tumour, which can 
promote and amplify immune responses. This resulted in significant therapeutic anti-tumour 
immunity, prolonged survival time and a tumour growth inhibition of 48%. In this study, the use of 
solid microneedles involved application of a microneedle array onto the naked abdominal skin which 
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was maintained in place for 2 min to create microchannels in the skin. After removal of the 
microneedle, the nanocomplex suspension was applied to the same region. This process is not ideal 
however with a double application required, limited loading capability due to the transient nature of 
the pores formed and the need for sharps disposal following use. 
 
For composite therapeutic gene delivery, dissolvable microneedles hold the most potential with 
release of the encapsulated therapeutic into the skin following application and subsequent  
dissolution [147]. McCaffrey et al present a novel approach where the RALA peptide is used to 
complex nucleic acids to form nanoparticles which are then incorporated into the polymer matrix of 
dissolvable microneedles [148]. It was found that the RALA/DNA nanoparticles retained their 
functionality following incorporation into the microneedles, and the physical strength and structure 
of the microneedle array was not compromised when loaded with the nanoparticles. In addition, the 
composite delivery platform was found to be functional both in vitro and in vivo. RALA/microneedle 
mediated delivery of a plasmid encoding for firefly luciferase resulted in systemic gene expression, 
observed in highly vascularised regions. This represents an exciting alternative strategy and 
highlights the potential of collaborative approaches to gene delivery and could be applied in a wide 
variety of applications. 
 
7. Future Perspective 
Cancer gene therapy has a therapeutic potential that has been unfulfilled so far, owing to the lack of 
a suitable delivery system. The existence of multiple extra- and intracellular barriers renders the 
design and engineering of a successful gene delivery vector extremely difficult, and despite the 
enormous amount of research ongoing in this area, the number of products gaining regulatory 
approval is extremely low. The development of systems such as MENDs and DBVs has shown that it 
is possible to create a complete multifunctional delivery vector and the possibility of creating an 
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‘artificial virus’ may not be totally unattainable. In addition to this, the advent of composite delivery 
systems, such as hydrogels and microneedles, has the potential to further the advancement of gene 
delivery. Many of the approaches discussed here are still at an early stage of development and much 
pre-clinical research is yet to be carried out before further advancement will be possible. The 
heterogeneous nature of cancer makes it highly unlikely that a ‘one size fits all’ approach will be 
effective and each cancer necessitates a tailor-made gene therapy approach.  
 
8. Executive Summary 
 
Barriers that prevent successful gene delivery 
• Extracellular barriers include packaging of nucleic acids, degradation of genetic cargo by 
nucleases in bodily fluids and opsonisation which triggers clearance from systemic circulation. 
• Intracellular barriers include internalisation to target cells, endosomal entrapment, immobility of 
DNA in the cytosol and nuclear import of DNA. 
Strategies to overcome extracellular barriers to gene delivery 
• Stealth molecules, such as polyethylene glycol (PEG), have been used in various delivery systems 
to avoid clearance and prolong systemic circulation time. 
• The PEG dilemma describes the problem where PEG may hinder the uptake of a vector into target 
cells. 
• Sheddable PEG systems with cleavable linkers allow PEG to be cleaved from the delivery system 
at the target tumour site, allowing cellular uptake of the vector. Cleavage is usually based on 
tumour microenvironment conditions such as pH or enzymes present. 
Strategies to overcome intracellular barriers to gene delivery 
• Internalisation to target cells has been promoted through receptor-mediated endocytosis via 
attachment of specific ligands to vectors. 
• Cell penetrating peptides have been very successful in enhancing cellular uptake and transfection 
efficiencies, especially arginine-rich peptides such as octa-arginine (R8). 
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• Endosomal escape may be facilitated through inclusion of histidine-rich polymers or peptides. 
Alternatively, fusogenic peptides promote escape through production of pores in the endosomal 
membrane.  
• RALA is a multifunctional peptide that can condense DNA, penetrate cell membranes and disrupt 
endosomes. 
• In the case of DNA therapeutics, trafficking towards the nucleus and nuclear import may be 
enhanced with the addition of a nuclear localisation signal (NLS). 
Multifunctional delivery systems 
• Multifunctional envelope-type nano devices (MEND) have been produced through clever design 
and a ‘programmed packaging’ concept. They incorporate a range of functional groups including 
DNA condensing cores, PEG, fusogenic peptides, R8 and targeting moieties to systematically 
overcome all barriers to gene delivery in turn.  
• Designer biomimetic vectors (DBVs) or designer biopolymers (DBPs), which comprise several 
peptide motifs are produced using recombinant DNA technology which allows control of vector 
characteristics at the molecular level. 
• Generally, DBVs possess a DNA-condensing motif (DCM), endosomal disruption motif (EDM), 
nuclear localisation motif (NLS) and targeting motif (TP), which have been shown to successfully 
overcome biological barriers. 
• Alternative delivery strategies which hold promise for gene delivery include composite delivery 
platforms, such as hydrogel matrices for prolonged release depot injections, and microneedles 
for the delivery of DNA vaccines via the skin. 
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